Compare Coursera Inc (COUR) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Crispr Therapeutics AG — how do they compare? Coursera Inc trades at $5.16 (market cap $1.39B), while Crispr Therapeutics AG trades at $53.39 (market cap $4.88B). The key difference: Crispr Therapeutics AG is far larger — about 3.5× Coursera Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Crispr Therapeutics AG for 77 Days on average.
| COUR | CRSP | |
|---|---|---|
Market Cap | $1.39B | $4.88B |
Volume | 9,728,980 | 2,861,747 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $74.92 |
52-Week Low | $4.64 | $44.34 |
Typical Hold Time | 47 Days | 77 Days |
Enterprise Value | $648.49M | $3.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COUR trades at $5.27, up 3.13% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages. Revenue growth is solid, rising from $524M in 2022 to $758M in 2025, yet the company remains unprofitable with a net loss of $51M in 2025. Recent news highlights AI platform developments and institutional interest, including large call option purchases and a new stake by Deutsche Bank AG.
The outlook is cautiously optimistic, driven by revenue growth and analyst consensus favoring a buy with a $7.40 price target. However, persistent losses, integration risks from acquisitions, and competitive pressures in edtech pose significant risks. Upside depends on converting subscriber growth into profitability.
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
